Drug intelligence / Profile preview

acyclovir + cyclosporin A

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Topical, Ophthalmic, Oral, Intravenous

Overview

A combination of the antiviral drug acyclovir and the immunosuppressive agent cyclosporin A. Acyclovir is a guanosine analog that inhibits viral DNA polymerase and DNA replication in herpesviruses, while cyclosporin A is an immunosuppressant that inhibits cyclophilin. This combination has been studied for use in herpetic stromal keratitis and may be used in transplant patients. However, co-administration requires careful monitoring due to increased risk of nephrotoxicity.

Targets

DNA polymerase familyPPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on acyclovir + cyclosporin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acyclovir + cyclosporin A.

Explore the full profile